precision medicine
precision medicine at Beyond Market Intelligence is a file of 3 stories. The newest of them: “A simple saliva test aligns cancer care with your body's internal clock”, “Evvy secures $40M to advance women's health through microbiome data”, and “Discover how better data unlocks AI's real potential in healthcare.”. Your treatment plan shouldn't ignore what time it is for your body. Evvy just raised $40 million in a Series B round led by Catalio Capital Management, and that's a meaningful vote of confidence for a company putting vaginal microbiome data at the center of women's health research. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work… The list below is every precision medicine story on Beyond Market Intelligence, newest first.
A simple saliva test aligns cancer care with your body's internal clock
Your treatment plan shouldn't ignore what time it is for your body. German startup TimeTeller has developed a simple saliva test kit that decodes your circadian rhythm, helping oncologists align cancer care with your internal clock. The goal is straightforward: fewer side effects, better outcomes. It's a practical, human-centered step toward making precision medicine feel less abstract. For more on biomolecular innovation, see our coverage of Giraffe Bio's copper-mining breakthrough.
Evvy secures $40M to advance women's health through microbiome data
Evvy just raised $40 million in a Series B round led by Catalio Capital Management, and that's a meaningful vote of confidence for a company putting vaginal microbiome data at the center of women's health research. It's about time this kind of data got serious backing. The funding can accelerate discoveries that have been underfunded for too long. If you're tracking how capital is moving through health innovation, this pairs well with our coverage on Wahlberg and Lee discussing wellness at Disrupt 2026.
Discover how better data unlocks AI's real potential in healthcare.
If AI is going to move the needle on cancer, it won't be through clever algorithms alone. This startup argues the real bottleneck is data, plain and simple. That's a refreshingly grounded take in a field prone to hype. We're not talking about magic; we're talking about feeding models the right, clean information. It's a messier problem than most want to admit, but it's the one that matters.